Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
(Incorporated in Cayman Islands with limited liability)
(Stock Code: 1681)
SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO THE ANNUAL REPORT
FOR THE YEAR ENDED 31 DECEMBER 2019
Reference is made to the annual report of Consun Pharmaceutical Group Limited (the "Company" ) for the year ended 31 December 2019 (the "Annual Report" ). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Annual Report.
In addition to the information provided in the paragraph headed "Share Option Scheme" in the Report of Directors and note 22(a) to the consolidated financial statements in the Annual Report, the Board would like to provide the following further information in relation to the share options for the year ended 31 December 2019:
Movements on the share options for the year ended 31 December 2019
Outstanding | Outstanding | |||||||||||
as at | Granted | Exercised | Cancelled | Lapsed | as at | |||||||
Tranche | 1 January | during | during | during | during | 31 December | ||||||
Number | 2019 | the year | the year | the year | the year | 2019 | ||||||
' 000 | ' 000 | ' 000 | ' 000 | ' 000 | ' 000 | |||||||
Directors | ||||||||||||
Mr. AN Yubao (1) | 2014 T3 (2) | 3,000 | - | - | - | - | 3,000 | |||||
2014 T4 (2) | 3,000 | - | - | - | - | 3,000 | ||||||
2016 T7 (2) | 1,200 | - | - | - | - | 1,200 | ||||||
2016 T8 (2) | 1,200 | - | - | - | - | 1,200 | ||||||
2016 T9 (2) | 1,600 | - | - | - | - | 1,600 | ||||||
2019 T4 (3) | - | 2,625 | - | - | - | 2,625 | ||||||
2019 T5 (3) | - | 2,625 | - | - | - | 2,625 | ||||||
2019 T6 (3) | - | 3,500 | - | - | - | 3,500 | ||||||
Sub-total | 10,000 | 8,750 | 0 | 0 | 0 | 18,750 | ||||||
1
Outstanding | Outstanding | ||||||||||||||
as at | Granted | Exercised | Cancelled | Lapsed | as at | ||||||||||
Tranche | 1 January | during | during | during | during | 31 December | |||||||||
Number | 2019 | the year | the year | the year | the year | 2019 | |||||||||
' 000 | ' 000 | ' 000 | ' 000 | ' 000 | ' 000 | ||||||||||
Ms. LI Qian (1) | 2014 T3 (2) | 3,000 | - | - | - | - | 3,000 | ||||||||
2014 T4 (2) | 3,000 | - | - | - | - | 3,000 | |||||||||
2016 T7 (2) | 1,200 | - | - | - | - | 1,200 | |||||||||
2016 T8 (2) | 1,200 | - | - | - | - | 1,200 | |||||||||
2016 T9 (2) | 1,600 | - | - | - | - | 1,600 | |||||||||
2019 T4 (3) | - | 2,625 | - | - | - | 2,625 | |||||||||
2019 T5 (3) | - | 2,625 | - | - | - | 2,625 | |||||||||
2019 T6 (3) | - | 3,500 | - | - | - | 3,500 | |||||||||
Sub-total | 10,000 | 8,750 | 0 | 0 | 0 | 18,750 | |||||||||
Professor ZHU Quan | 2014 T1 (2) | 720 | - | - | - | - | 720 | ||||||||
2014 T2 (2) | 480 | - | - | - | - | 480 | |||||||||
2016 T4 (2) | 600 | - | - | - | - | 600 | |||||||||
2016 T5 (2) | 358 | - | - | - | - | 358 | |||||||||
2016 T6 (2) | 800 | - | - | - | (470) | 330 | |||||||||
2019 T1 (3) | - | 240 | - | - | - | 240 | |||||||||
2019 T2 (3) | - | 240 | - | - | - | 240 | |||||||||
2019 T3 (3) | - | 320 | - | - | - | 320 | |||||||||
Sub-total | 2,958 | 800 | 0 | 0 | (470) | 3,288 | |||||||||
Mr. TANG Ning | 2014 T1 (2) | 230 | - | - | - | - | 230 | ||||||||
2014 T2 (2) | 119 | - | - | - | - | 119 | |||||||||
2016 T1 (2) | 287 | - | - | - | - | 287 | |||||||||
2016 T2 (2) | 270 | - | - | - | - | 270 | |||||||||
2016 T3 (2) | 600 | - | - | - | (216) | 384 | |||||||||
2019 T1 (3) | - | 390 | - | - | - | 390 | |||||||||
2019 T2 (3) | - | 390 | - | - | - | 390 | |||||||||
2019 T3 (3) | - | 520 | - | - | - | 520 | |||||||||
Sub-total | 1,506 | 1,300 | 0 | 0 | (216) | 2,590 | |||||||||
2
Outstanding | Outstanding | ||||||||||||||
as at | Granted | Exercised | Cancelled | Lapsed | as at | ||||||||||
Tranche | 1 January | during | during | during | during | 31 December | |||||||||
Number | 2019 | the year | the year | the year | the year | 2019 | |||||||||
' 000 | ' 000 | ' 000 | ' 000 | ' 000 | ' 000 | ||||||||||
Employees | |||||||||||||||
In aggregate | 2014 T1 (2) | 3,266 | - | - | - | - | 3,266 | ||||||||
2014 T2 (2) | 3,266 | - | - | - | - | 3,266 | |||||||||
2016 T1 (2) | 7,190 | - | (208) | - | (1,014) | 5,968 | |||||||||
2016 T2 (2) | 7,190 | - | (208) | - | (1,014) | 5,968 | |||||||||
2016 T3 (2) | 9,587 | - | (277) | - | (1,352) | 7,958 | |||||||||
2019 T1 (3) | - | 13,020 | - | - | (1,116) | 11,904 | |||||||||
2019 T2 (3) | - | 13,020 | - | - | (1,116) | 11,904 | |||||||||
2019 T3 (3) | - | 17,360 | - | - | (1,488) | 15,872 | |||||||||
Sub-total | 30,499 | 43,400 | (693) | 0 | (7,100) | 66,106 | |||||||||
Total | 54,963 | 63,000 | (693) | 0 | (7,786) | 109,484 | |||||||||
Notes:
- a substantial shareholder of the Company
- Share options granted before 1 January 2019:
Date of Grant | ||||||
as per | ||||||
Tranche | Board' s | Exercise | ||||
Number | approval | Vesting Period | Exercise Period | Price | ||
from | to | from | to | |||
DD/MM/YYYY | DD/MM/YYYY | DD/MM/YYYY | DD/MM/YYYY | DD/MM/YYYY | HKD | |
2014 T1 | 24/03/2014 | 24/03/2014 | 23/03/2015 | 24/03/2015 | 23/03/2024 | 6.64 |
2014 T2 | 24/03/2014 | 24/03/2014 | 23/03/2016 | 24/03/2016 | 23/03/2024 | 6.64 |
2014 T3 | 24/03/2014 | 28/05/2014* | 23/03/2015 | 24/03/2015 | 23/03/2024 | 6.64 |
2014 T4 | 24/03/2014 | 28/05/2014* | 23/03/2016 | 24/03/2016 | 23/03/2024 | 6.64 |
2016 T1 | 01/04/2016 | 01/04/2016 | 31/03/2017 | 01/04/2017 | 31/03/2026 | 4.01 |
2016 T2 | 01/04/2016 | 01/04/2016 | 31/03/2018 | 01/04/2018 | 31/03/2026 | 4.01 |
2016 T3 | 01/04/2016 | 01/04/2016 | 31/03/2019 | 01/04/2019 | 31/03/2026 | 4.01 |
2016 T4 | 01/04/2016 | 01/04/2016 | 31/03/2017 | 01/04/2017 | 31/03/2026 | 4.01 |
2016 T5 | 01/04/2016 | 01/04/2016 | 31/03/2018 | 01/04/2018 | 31/03/2026 | 4.01 |
2016 T6 | 01/04/2016 | 01/04/2016 | 31/03/2019 | 01/04/2019 | 31/03/2026 | 4.01 |
2016 T7 | 01/04/2016 | 27/05/2016* | 31/03/2017 | 01/04/2017 | 31/03/2026 | 4.01 |
2016 T8 | 01/04/2016 | 27/05/2016* | 31/03/2018 | 01/04/2018 | 31/03/2026 | 4.01 |
2016 T9 | 01/04/2016 | 27/05/2016* | 31/03/2019 | 01/04/2019 | 31/03/2026 | 4.01 |
- the date on which the relevant shareholders' approval was granted
3
3. Share options granted during the year ended 31 December 2019:
Date of Grant | |||||||
Tranche | as per Board' s | Exercise | Option | ||||
Number | approval | Vesting Period | Exercise Period | Price | Value | ||
from | to | from | to | ||||
DD/MM/YYYY | DD/MM/YYYY | DD/MM/YYYY | DD/MM/YYYY | DD/MM/YYYY | HKD | HKD | |
2019 T1 | 02/01/2019 | 02/01/2019 | 31/03/2020 | 01/04/2020 | 01/01/2029 | 4.476 | 1.4434 |
2019 T2 | 02/01/2019 | 02/01/2019 | 31/03/2021 | 01/04/2021 | 01/01/2029 | 4.476 | 1.4900 |
2019 T3 | 02/01/2019 | 02/01/2019 | 31/03/2022 | 01/04/2022 | 01/01/2029 | 4.476 | 1.5317 |
2019 T4 | 02/01/2019 | 31/05/2019* | 31/03/2020 | 01/04/2020 | 01/01/2029 | 4.476 | 1.9825 |
2019 T5 | 02/01/2019 | 31/05/2019* | 31/03/2021 | 01/04/2021 | 01/01/2029 | 4.476 | 2.0625 |
2019 T6 | 02/01/2019 | 31/05/2019* | 31/03/2022 | 01/04/2022 | 01/01/2029 | 4.476 | 2.1216 |
- the date on which the relevant shareholders' approval was granted
During the year ended 31 December 2019, the Board approved the grant of 63,000,000 share options to certain Directors and eligible employees of the Group on 2 January 2019 with an exercise price of HKD4.476 and the closing price of the Company' s shares immediately before the date of such grant was HKD4.55.
During the year ended 31 December 2019, all of the 693,000 exercised share options were exercised by the Group' s employees at the exercise price of HKD4.01 and the weighted average closing price of the Company' s shares immediately before the dates on which such share options were exercised was HKD4.8196.
The share option value is measured based on a binomial tree model and the total value of share options granted during the year ended 31 December 2019 is as follows:
Total value of | ||
Share options granted to: | share options | |
HKD' 000 | ||
Directors | ||
Mr. AN Yubao * | 18,044 | |
Ms. LI Qian * | 18,044 | |
Professor ZHU Quan | 1,194 | |
Mr. TANG Ning | 1,940 | |
Employees | ||
In aggregate | 64,783 | |
Total | 104,005 | |
- a substantial shareholder of the Company
The total value of share options granted is charged to profit or loss as part of staff costs over the vesting period taking into account the probability that the share options will vest.
4
In addition, the remaining life of the Share Option Scheme, which will expire on 1 December 2023, is approximately 3 years 8 months from the date of the Annual Report (i.e. 23 March 2020) and there is no minimum period for which a share option must be held before it can be exercised pursuant to the terms of the Share Option Scheme.
The above additional information does not affect other information contained in the Annual Report. Save as disclosed in this announcement, all other information in the Annual Report remains unchanged.
By order of the Board
Consun Pharmaceutical Group Limited
AN Yubao
Chairman of the Board
Hong Kong, 26 August 2020
As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive Directors.
5
Attachments
- Original document
- Permalink
Disclaimer
Consun Pharmaceutical Group Ltd. published this content on 26 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 August 2020 11:11:04 UTC